Clinician-focused platform reaches 96% accuracy on the United States Medical Licensing Examination (USMLE), outperforming industry peers on standardized tests
Pathway today announced that its proprietary large-language model (LLM) scored 96% on a validated set of United States Medical Licensing Examination (USMLE) questions, the highest accuracy yet reported for a specialized medical AI. The result strengthens Pathway’s position as a leading evidence-based decision-support tool for frontline clinicians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250502879071/en/
Pathway’s AI models top the publicly reported leaderboard on the U.S. Medical Licensing Examination (USMLE). Pathway Deep achieved a 96 % accuracy rate and Pathway Think reached 94 %, outperforming other medical‑AI systems such as GPT‑4, Med‑Gemini, OpenEvidence, and Hippocratic AI. These results underscore Pathway’s commitment to delivering safe, high‑precision clinical reasoning tools for clinicians and medical learners worldwide.
In head-to-head testing, Pathway’s “Deep” AI model surpassed domain-specific peers MediSearch Pro, OpenEvidence and Hippocratic AI, and outperformed generalist systems such as ChatGPT 4o, o1, and GPT-4.5 on complex diagnostic scenarios. Independent academic validation studies are currently underway to further corroborate these groundbreaking results.
Pathway attributes the performance to its transparent just-in-time reasoning pipeline, which combines retrieval-augmented generation (RAG) with chain-of-thought (CoT) analysis and agentic tool calling. The architecture allows the model to evaluate multiple information sources simultaneously, surface potential knowledge gaps, generate follow-up questions, and apply clinical scoring and prediction rules—all without adding latency for the user.
“Trust and transparency are foundational for bringing AI into clinical workflows,” said Dr. Louis Mullie, Chief Medical Officer at Pathway. “Clinicians need speed and accuracy, but they also need verifiable evidence. Pathway’s assistant reveals its reasoning step-by-step and links every recommendation to expert-vetted guidelines and a comprehensive drug reference. By giving users the context to double-check dosages and key guidance, Pathway helps them leverage AI efficiently while maintaining full control over patient-safety decisions.”
This milestone builds on Pathway’s rapid growth and industry recognition. In 2024 Pathway became the first generative-AI medical tool to receive continuing-medical-education (CME) co-accreditation, making every clinical question asked through the platform eligible for CME credit. Earlier this year the company added HIPAA support for Pathway Plus subscribers, enabling secure, compliant integration of patient-specific data into AI queries. Pathway also recently surpassed one million registered users across more than 10,000 healthcare institutions, underscoring its widespread adoption and trust within the medical community.
About Pathway
Pathway helps clinicians deliver better, faster, safer care by providing instant, evidence-based answers to medical questions. With 1 million+ registered healthcare professionals spanning 10,000 care centers, the AI-powered platform has established a strong presence across the United States and internationally.
To learn more or try Pathway, visit www.pathway.md
View source version on businesswire.com: https://www.businesswire.com/news/home/20250502879071/en/
Pathway "Deep" achieves 96 % accuracy on the USMLE, the highest publicly reported score for any medical AI model.
Contacts
For media inquiries, contact press@pathway.md